# Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05740566/  
OnCo record `nct05740566` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in which amrubicin is one of the standard comparator treatments, run by Amgen in small-cell lung cancer, active.

## Summary

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05740566 by Amgen, with 509 participants enrolled, started 2023-05-31. Conditions listed: Small Cell Lung Cancer (SCLC). Amrubicin is a comparator arm, not the drug under test. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05740566
- Phase: 3
- Setting: A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
- Sponsor: Amgen
- Enrolled: 509

## Sources

- ClinicalTrials.gov NCT05740566: https://clinicaltrials.gov/study/NCT05740566

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Amrubicin](https://onco.cc/drugs/amrubicin/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct05740566.json